PRLog (Press Release) –
Mar 16, 2007 – Acomplia was a ground-breaking new breed of medication which targeted the body’s little understood endocannabinoid system when it was launched in the UK last June but it could soon have one or more rivals. Both Merck and Pfizer have similar drugs in Phase III clinical trials which are said to be producing very promising results. Merck has already announced that it intends to apply for regulatory approval in 2008 and it is believed that Pfizer will be aiming to seek approval at around the same time. There is another drug which works in a similar way to Acomplia under development by Bristol Myers Squibb but it is believed that the development of this product is significantly behind those of Merck and Pfizer.
For more detailed information on acomplia diet pills visit: http://buyacompliadietpills.blog.co.uk/
